Karyopharm Reports Data For Selinexor From Ongoing Phase 1 Trial - Quick Facts

(RTTNews) - Karyopharm Therapeutics Inc. (KPTI) announced clinical data from an ongoing Phase 1 trial of its lead drug candidate, Selinexor (KPT-330), in patients with hematologic malignancies. The company said the data indicated that Selinexor showed continued evidence of anti-cancer activity as a single agent in patients with heavily pretreated Non-Hodgkin's Lymphoma (NHL) and Acute Myeloid Leukemia (AML) who had progressive disease on study entry.

"We continue to be encouraged by the results and tolerability of oral Selinexor. The data further demonstrate the potential of Selinexor as a single agent for patients with relapsed or refractory hematologic malignancies who had previously progressed after available therapies," said Sharon Shacham, Karyopharm's Founder, President and Chief Scientific Officer.

"We have been similarly impressed with the activity of Selinexor in patients with AML. The data further support our decision to move forward with registration-directed studies in AML, Richter's Syndrome and DLBCL," Sharon Shacham, said.